We found that the treatment with Bafetinib considerably turns off Lyn phosphorylation at Tyr396 active site although the presence of MSCs; the same effect was also observed after treating CLL B cells with Ibrutinib (Figure 7B, row b). This evidence concerns the gene LYN and B-cell chronic lymphocytic leukemia.